Relapsing multiple sclerosis (RRMS) is a chronic inflammatory disease of the central nervous system characterized by the destruction of the myelin sheath of nerve fibers, which leads to a disruption in the transmission of nerve impulses. This form of multiple sclerosis is one of the most common and difficult to predict forms of the disease, manifesting itself in the form of relapses and remissions. Clinical neurological symptoms can vary from mild to severe and include visual, motor and sensory impairments. RRMS often affects young people aged 20 to 40 years, which creates a significant social and economic burden for patients and society as a whole.
History of the disease and interesting historical facts
The history of multiple sclerosis goes back more than a hundred years, beginning with the first descriptions of the disease in the 19th century. One of the first to identify this disease as an independent nosological entity was the Swiss physician Jean-Martin Charcot in 1868. He described many clinical manifestations and conducted anatomical studies that confirmed the presence of myelin damage. An important event was the discovery in 1916 of the concept of "interferons" and their role in the pathogenesis of MS. Throughout the 20th century, research was aimed at finding causes, mechanisms of development and methods of treatment; significant advances were achieved in the field of pharmacotherapy in the last third of the century. In recent decades, intensive study of genetic, environmental and immunobiological factors has led to significant progress in understanding and preventing the disease.
Epidemiology
The epidemiology of multiple sclerosis shows that incidence varies with geographic location and genetic factors. According to the World Health Organization, there are approximately 2.8 million people with MS worldwide, with 1.2 to 2.5 cases per 100,000 population registered each year. Incidence is higher in northern hemisphere countries, particularly Scandinavian countries and Canada, while equatorial regions have significantly lower incidence. Researchers have therefore begun to study factors that contribute to increased incidence in certain regions, including climate conditions, sunlight exposure, and the presence of certain viruses.
Genetic predisposition to this disease
Genetic predisposition plays a significant role in the development of multiple sclerosis, although the specific mechanisms remain unclear. According to twin studies, the risk of developing MS in identical twins is about 30%, while for fraternal twins it does not exceed 5%. Certain alleles of the major histocompatibility complex (HLA) have been associated with an increased risk, especially HLA-DRB1*15:01. In addition, mutations have been identified in genes such as IL2RA, which are also involved in the immune response. Genome analysis has revealed many polygenic variants that contribute to predisposition to this disease, which emphasizes the multifactorial nature of its development, the interaction of genetic and environmental factors.
Risk factors for the development of this disease
Risk factors associated with the development of relapsing multiple sclerosis can be divided into several categories:
- Genetic factors: predisposition due to the presence of certain genes.
- Environmental factors: sunlight levels, geographic location.
- Infectious factors: Infections such as the Epstein-Barr virus may contribute to the development of the disease.
- Immune factors: changes in the functioning of the immune system.
- Others: smoking, being overweight in adolescence, and vitamin D deficiency.
The combination of these factors can significantly increase the risk of developing RMS, which highlights the importance of a comprehensive approach to prevention and early detection of the disease.
Diagnosis of this disease
Diagnosis of relapsing multiple sclerosis is based on the clinical picture, laboratory and radiological studies. The main symptoms to pay attention to include:
- Short-term or permanent visual disturbances (blurred vision, double vision).
- Loss of sensation or paresthesia (numbness, tingling).
- Movement disorders (weakness of strength, spasticity).
- Inadequate sprinter coordination and balance.
- Cognitive impairment (difficulty with memory and attention).
Laboratory studies may include cerebrospinal fluid analysis for myelin-basic proteins and increased lymphocytes. Radiological examinations such as magnetic resonance imaging (MRI) are key diagnostic tools to identify characteristic changes such as perineurotic and subcortical lesions. Differential diagnosis with other neurological diseases such as Devic's disease, myasthenia gravis, and vascular pathology is important.
Treatment
Treatment of relapsing multiple sclerosis is complex and includes both pharmacological and non-pharmacological approaches. The main goals of therapy are to reduce the frequency of relapses, slow the progression of the disease and improve the patient's quality of life. Pharmacological treatment includes:
- Glucocorticosteroids to relieve exacerbations.
- Immunosuppressants (methotrexate, azathioprine).
- Immunomodulators (interferon beta, gibracaramine, natalizumab).
In addition, there are non-pharmacological methods, such as physiotherapy, psychosocial support, diet therapy. Surgical treatment is used extremely rarely and, as a rule, is not the main method in the treatment of RMS. An important aspect of treatment is also the individualization of the approach depending on the clinical picture and the patient's condition.
List of drugs used to treat this disease
The list of drugs used to treat relapsing multiple sclerosis includes:
- Interferon beta-1a (Avonex, Rebif)
- Interferon beta-1b (Betaferon)
- Glaeteramer acetate (Copaxone)
- Natalizumab (Tysabri)
- Ocrelizumab (Ocrevus)
- Фingolimod (Gilanya)
- Alentizumab (Lemtrida)
These drugs are aimed at reducing the frequency of relapses and slowing the progression of the disease.
Disease monitoring
Monitoring relapsing multiple sclerosis involves regular examinations and monitoring of the patient's condition. Control stages include:
- May examinations to assess psycho-emotional state.
- MRI to assess disease activity and dynamics of demyelination foci.
- Monitoring the level of activity of immune cells and biomarkers in the blood.
The prognosis for patients with RMS can vary depending on many factors, including age at onset, gender, genetic predisposition, and response to therapy. Potential complications may include physical disability, cognitive impairment, and secondary complications such as infections.
Age-related features of the disease
Multiple sclerosis can present differently depending on the age of the patient. Younger patients tend to have more aggressive forms with a high rate of relapse. Older patients may progress more slowly but often have more severe neurological deficits. Children and adolescents also tend to have specific clinical manifestations, such as behavioral changes and learning difficulties.
Questions and Answers
- What causes relapsing multiple sclerosis? The exact cause is unknown, but scientific research points to a combination of genetic, environmental and infectious factors.
- What are the main symptoms of RMS? Symptoms may include visual disturbances, paresthesia, movement disorders, problems with coordination, and cognitive impairment.
- Can relapsing multiple sclerosis be cured? There is currently no complete cure, but there are treatments that can help control the disease and improve quality of life.
- What medications are used to treat RMS? The main drugs include interferons, glucocorticosteroids, immunomodulators and other specific agents.
- Is continuous monitoring necessary for RMS? Yes, monitoring the disease status is an important part of patient management to adapt therapy and monitor progression.
